Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as recommendations or advice for any financial actions [1]. - The content is not tailored to individual financial situations or needs, highlighting the necessity for users to apply their own discretion [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - Users are encouraged to perform their own research and understand the risks involved before investing in any financial instruments [1].

Core Viewpoint - Exelixis has announced a new share repurchase program worth up to $500 million, which has positively impacted its stock price amidst a generally declining market [1][2]. Group 1: Share Repurchase Program - Exelixis will initiate a new share repurchase program authorized for up to $500 million before December 31, following the exhaustion of the current buyback program [2]. - The company expects the current buyback program, also capped at $500 million, to be completed in the second calendar quarter of this year [2]. - This new initiative marks Exelixis's fourth share repurchase program, with over $1.2 billion spent on buybacks through the end of 2024 [3]. Group 2: Market Reaction - Following the announcement of the new buyback program, Exelixis's shares rose by 5%, contrasting with a 1.7% decline in the S&P 500 index on the same day [1]. - Investors generally view stock repurchase announcements favorably, as they indicate management's commitment to supporting equity value [4].

Core Insights - Exelixis, Inc. has authorized an additional stock repurchase program of up to $500 million, expected to be completed by Q2 2025 [1] - The company reported a fourth-quarter adjusted EPS of 55 cents, exceeding the consensus estimate of 43 cents, with sales of $566.75 million, also surpassing expectations [2] - Exelixis reaffirmed its 2025 sales guidance of $2.15 billion to $2.25 billion, slightly below the consensus of $2.24 billion [2] Stock Repurchase Program - The new stock repurchase program follows a previous $500 million program announced in August 2024, which is set to be completed in Q2 2025 [1] - As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through its stock repurchase initiatives [1] Financial Performance - The fourth-quarter adjusted EPS of 55 cents beat the consensus estimate of 43 cents, indicating strong financial performance [2] - Sales for the quarter reached $566.75 million, exceeding the consensus of $563.42 million, reflecting robust demand for its products [2] - The company has reaffirmed its sales guidance for 2025, projecting revenues between $2.15 billion and $2.25 billion [2] Clinical Developments - Exelixis announced positive long-term results from the phase 3 CheckMate -9ER trial for Cabometyx in combination with Opdivo, showing sustained efficacy benefits for patients with advanced renal cell carcinoma [3][4] - The trial demonstrated improved progression-free survival and overall survival compared to sunitinib, with a median follow-up of 67.6 months [4] - A subgroup analysis indicated that the combination therapy favored Cabometyx regardless of the IMDC risk group [5] Regulatory Updates - The supplemental New Drug Application (sNDA) for cabozantinib for advanced pancreatic neuroendocrine tumors is still under FDA consideration, with an action date set for April 3 [6] - The sNDA will not be discussed at the upcoming FDA Oncologic Drugs Advisory Committee meeting [6] Stock Performance - Exelixis stock experienced a 3.42% increase, reaching $36.29 at the last check on Friday [6]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy wit ...

Last week, Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results.EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered adjusted earnings of 33 cents per share in the year-ago quarter. The outperformance was mainly driven by higher revenues.Including stock-based compensation expense, earnings were 48 cents per share in the reported quarter.Net revenues were $566.7 million, which beat the Zacks Consensus Estimate of $563 ...

Did you analyze how Exelixis (EXEL) fared in its international operations for the quarter ending December 2024? Given the widespread global presence of this drug developer, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inves ...

Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results.EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered adjusted earnings of 33 cents per share in the year-ago quarter. The outperformance was mainly driven by higher revenues.Including stock-based compensation expense, earnings were 48 cents per share in the reported quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Net revenues were $566 ...

Exelixis (NASDAQ: EXEL ) has done well marketing the multi-kinase inhibitor, cabozantinib, bringing in $1.81B in net product revenues in 2024. The party will one day end, however, as EXEL has already agreed to allow generics manufacturerScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: ...

Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Ci ...

For the quarter ended December 2024, Exelixis (EXEL) reported revenue of $566.76 million, up 18.2% over the same period last year. EPS came in at $0.55, compared to $0.33 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $563.12 million, representing a surprise of +0.65%. The company delivered an EPS surprise of +7.84%, with the consensus EPS estimate being $0.51.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...